CD274 and neoplasm: The application of biomarkers related to gene expression profiles and TME such as TIL, tumor mutational burden (TMB), mismatch repair deficient (dMMR), etc. in combination with or replacing PD-L1 expression to predict the efficacy of immunotherapy has been widely studied [85].